- 01Urinary symptoms track the inner prostate; early cancer grows in the outer one
Most prostate cancers start in the outer (peripheral) zone of the gland, away from the urethra 10. Benign enlargement (BPH) grows in the inner (transition) zone that wraps the urethra, and BPH is what slows the stream and wakes men at night. So a urinary symptom is usually BPH (the American Cancer Society says trouble urinating is "much more likely to be the result of" BPH 1), and having no symptoms is no proof that prostate cancer is absent. A PSA test, a rectal exam and an MRI find early prostate cancer; symptoms rarely do.
Early prostate cancer usually causes no symptoms 1. It tends to grow in the outer part of the prostate, away from the urethra 10, so a cancer can be present for years without changing how a man pees. The prostate is a walnut-sized gland below the bladder that wraps around the urethra, the tube that carries urine out. Prostate cancer is the most common cancer in American men after skin cancer, with about 313,780 new cases and 35,770 deaths projected in the US for 2025 3.
Why early prostate cancer is usually silent
Yes, you can have prostate cancer without symptoms; in early disease it is the usual case. The prostate has zones. About 7 in 10 prostate cancers start in the outer zone (the peripheral zone) 10, the part a doctor can feel through the rectum and the part farthest from the urethra. Benign prostatic hyperplasia (BPH), the non-cancer enlargement that comes with age, grows in the inner zone (the transition zone) that wraps around the urethra like a collar. As BPH tightens that collar, the stream weakens and the bladder stops emptying fully. A small cancer in the outer zone presses on nothing, so it changes nothing a man can feel.
Most of the symptoms above are more likely to be caused by something other than prostate cancer. For example, trouble urinating is much more likely to be the result of benign prostatic hyperplasia (BPH), a noncancerous growth of the prostate.American Cancer Society, Signs and symptoms of prostate cancer 1
The symptoms, one by one
The first signs of prostate cancer, when there are any, are the ones below, and every one has a more common, harmless cause.
| Symptom | What you notice | Usual innocent cause | Get it checked when |
|---|---|---|---|
| Weak or stop-start stream | Urine comes slowly, stops and starts, or dribbles at the end | BPH | It is new, getting worse, or bothers you |
| Trouble starting (hesitancy) | Standing and waiting before urine flows | BPH, some cold and allergy medicines | Within a few weeks of noticing it |
| Peeing often or at night | Going every hour or two; waking two or more times a night | BPH, drinking late, caffeine, alcohol, diabetes | It is new or keeps getting worse |
| Feeling you have not emptied | Needing to go again soon after you finish | BPH, overactive bladder | Book within days; same day if you cannot pass urine at all |
| Blood in urine | Pink, red or cola-colored urine; on a dipstick, urine blood | Infection, kidney stones, hard exercise | Any visible blood: see a doctor within days |
| Blood in semen | Red or brown semen | Recent biopsy, infection, an inflamed gland; often no cause is found | It keeps coming back, you are over 40, or other symptoms come with it |
| Erection problems | Erections harder to get or keep | Blood vessel disease, diabetes, low testosterone, medicines; see erectile dysfunction | At your next visit, sooner if it is sudden |
| Pain on ejaculation or pelvic ache | Ache between scrotum and anus, or pain when you climax | Prostatitis (an inflamed or infected prostate) | Within days; same day with fever |
Because these symptoms cannot separate cancer from BPH, the UK NICE guideline on suspected cancer asks family doctors to consider a PSA test and a rectal exam in men with any lower urinary tract symptom (waking at night to pee, peeing often, trouble starting, sudden urges, or not emptying), erection problems, or visible blood in the urine 2. As our frequent urination guide puts it: "Peeing often with small amounts each time points to the bladder: infection, an overactive bladder or a large prostate." Most men checked this way do not have cancer: only about 1 in 4 men who go on to a biopsy for a raised PSA turn out to have it 14.
Signs prostate cancer may have spread
Bone is by far the most common place prostate cancer spreads, involved in about 8 in 10 men whose cancer has spread 12, so the main late symptom is bone pain in the lower back, hips, pelvis or ribs 1, often a deep ache that is worse at night and does not ease with rest. Other signs of spread are weight loss you cannot explain (see unexplained weight loss), tiredness and breathlessness from anemia, numbness or weakness in the hips, legs or feet, swelling in one or both legs when lymph nodes are blocked, and a bone that breaks after a minor fall. Back pain with leg weakness, numbness or new trouble controlling the bladder or bowel is the emergency in the box at the top of this page: get care the same day 13.
When to get help
- 1Go nowAny of the emergencies in the box at the top of this page: go to the emergency department or call 911.
- 2Book within daysVisible blood in the urine, bone pain you cannot explain, weight loss you cannot explain, or urinary symptoms that came on quickly.
- 3Book within a few weeksA slower stream, night-time peeing, blood in semen that keeps returning, or new erection problems.
- 4Bring your family historyTell the doctor if a father or brother had prostate cancer, or if close relatives had breast, ovarian or pancreatic cancer or carry a BRCA variant (an inherited gene change that raises cancer risk). It changes how early and how often PSA makes sense 7.
Is it cancer, an enlarged prostate or prostatitis?
Three prostate conditions share most symptoms and can all raise PSA; age, pain and fever separate them better than urinary symptoms do.
| Enlarged prostate (BPH) | Prostatitis | Prostate cancer | |
|---|---|---|---|
| Who gets it | The most common prostate problem in men over 50; rarely causes symptoms before 40 11 | Men of any age; common under 50 | Mostly men over 65; rare before 40 8 |
| Typical symptoms | Weak stream, night-time peeing, urgency, dribbling | Pain in the pelvis or between the scrotum and anus, burning, pain on ejaculation; fever if acute | Usually none early; urinary symptoms if large or advanced |
| Pain | Rare | Common | Uncommon early; bone pain if spread |
| PSA | Can be mildly raised | Can rise sharply, then fall after treatment | Often raised, sometimes normal |
| What sorts it out | Exam, PSA, urine test, symptom score | Urine test and culture, exam | PSA, MRI, then biopsy |
BPH does not turn into prostate cancer, but a man can have both at once, and BPH symptoms can be the reason a hidden cancer gets found. Saw palmetto is a popular supplement for urinary symptoms, but in two large placebo-controlled trials it worked no better than a placebo for them 18 19, and it does not treat or prevent prostate cancer. It is no reason to put off a PSA test and an exam.
Who is most at risk
Age is the biggest risk factor. Prostate cancer is rare before 40, the chance rises quickly after 50, and about 6 in 10 cases are diagnosed at 65 or older 8, so urinary symptoms in a man over 50 deserve a talk about PSA. Black ancestry raises both the chance of prostate cancer and the chance of dying of it 3. A father or brother with prostate cancer more than doubles a man's risk 9, and inherited variants such as BRCA2 raise it further and are linked to more aggressive disease; a family history of breast, ovarian or pancreatic cancer can be the clue. Studies of vasectomy have given mixed results, with no clear link to prostate cancer 9.
The blood tests that point to it
PSA (prostate-specific antigen) is a protein made by prostate cells that leaks into the blood more when the gland is enlarged, inflamed or cancerous. A total PSA above 4.0 ng/mL is the flag most US labs use and the one the US PLCO screening trial used; the European ERSPC trial mostly used 3.0 4. Age-based upper limits run lower in younger men: about 2.5 ng/mL in your 40s, 3.5 in your 50s, 4.5 in your 60s and 6.5 in your 70s 15; the PSA page has the full ranges. As our high PSA guide puts it: "The number says something is happening in the prostate; the repeat test, free PSA, MRI and biopsy say what." Finasteride and dutasteride lower PSA by about half 17, and biotin can distort some PSA tests.
Example total PSA result in a 60-year-oldng/mL
In that 4 to 10 ng/mL grey zone, the free-to-total PSA ratio helps. Prostate cancer cells release PSA that is more tightly bound to blood proteins, so a low share of free PSA leans toward cancer: under about 10% free carries the highest chance, and over about 25% the lowest 16. Some routine results matter only in advanced disease: a raised alkaline phosphatase (ALP) can come from bone spread (see bone markers explained), a low hemoglobin from anemia, and a raised creatinine or a falling eGFR from urine backing up into the kidneys. No blood test can confirm or rule out prostate cancer; the tumor markers guide explains why.
The blood markers to read beside prostate symptoms

What happens after a raised PSA or a worrying symptom
The modern workup for prostate cancer puts an MRI before the needle, which spares many men a biopsy. The usual order:
- Repeat the PSA under clean conditions: no ejaculation or long bike ride for about two days, no active urine infection (see how to prepare for a blood test). A single high reading often comes back lower.
- Rectal exam: the doctor feels the back of the prostate, the outer zone where most prostate cancers start, for a hard lump or uneven edge.
- MRI of the prostate, scored PI-RADS 1 to 5 for how likely a significant cancer is. In the PRECISION trial, MRI first with a targeted biopsy found clinically significant cancer in 38% of men versus 26% with a standard biopsy, and 28% of men in the MRI group avoided a biopsy because the scan was not suspicious 5.
- Targeted biopsy: thin needles take samples from suspicious areas, now often through the skin between the scrotum and anus (transperineal), which carries a lower infection risk.
- Grading: a pathologist gives a Gleason score, reported as Grade Group 1 to 5. Grade Group 1 is slow-growing and is usually watched; Grade Groups 4 and 5 are aggressive. Genomic tests on the biopsy tissue, such as Decipher, Oncotype DX Prostate and Prolaris, can help decide between watching and treating.
- Staging for higher-risk cancers: a PSMA PET scan, which uses a tracer that sticks to prostate cancer cells, or CT and bone scans show whether the cancer has left the gland.
Your doctor may add a check before the MRI. The Prostate Health Index (PHI) and the 4Kscore combine several forms of PSA into one risk score, and a urine test (SelectMDx) looks for genes linked to prostate cancer. PSA density divides PSA by prostate size on MRI, so a big but harmless gland is not held against you.
Should you be screened without symptoms?
Screening finds prostate cancer early but also finds slow cancers that would never have caused harm. In the European ERSPC trial, inviting men to screening cut prostate cancer deaths by about 20% over 16 years; 570 men had to be invited and 18 diagnosed to prevent one death 20. The USPSTF estimates that for every 1,000 men aged 55 to 69 screened over about 13 years, around 1.3 avoid death from prostate cancer and about 3 avoid cancer that spreads, while 20% to 50% of screen-found cancers may be overdiagnosed (found and labelled, but never going to cause harm), and false alarms lead to biopsies with pain, bleeding and infection 4.
The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older.US Preventive Services Task Force, JAMA 2018 4
| Guideline | Who | Starting age | How often |
|---|---|---|---|
| USPSTF 2018 4 | Average-risk men | 55 to 69: an individual choice after talking through benefits and harms; not advised from 70 | Not set; left to you and your clinician |
| AUA/SUO 2023, the main US urology societies 7 | Average-risk men | Baseline PSA at 45 to 50; regular screening 50 to 69 | Every 2 to 4 years |
| AUA/SUO 2023 7 | Black ancestry, BRCA2 or other inherited variants, strong family history | 40 to 45 | Every 2 to 4 years |
| NHS (UK) 24 | Any man | No population screening program; a PSA test on request after a talk with a GP | Agreed with the GP |
For men with symptoms, screening rules do not apply: a PSA test is part of the normal workup 2. If you do screen, the trend over years matters more than one PSA; blood tests for men and the tumor and screening markers hub cover the other checks.
Treatment options in general terms
Treatment depends on grade, stage, PSA, age, other health conditions and what a man wants to protect, and the choice is made with a urologist and often a radiation oncologist:
- Active surveillance: regular PSA tests, MRI and repeat biopsies for low-risk prostate cancer, with treatment only if the cancer shows signs of growing.
- Surgery (radical prostatectomy): removal of the whole gland, usually robot-assisted.
- Radiotherapy: external beam radiation or seeds placed inside the gland (brachytherapy), often with a course of hormone therapy for higher-risk cancers.
- Hormone therapy (androgen deprivation therapy, ADT): drugs that drive testosterone to very low levels, because prostate cancer feeds on it. The symptoms that follow look like severe low testosterone, and a total testosterone test confirms the drug is working.
- Treatments for advanced prostate cancer: newer hormone-blocking drugs, chemotherapy, PSMA-targeted radiation given by vein, and targeted drugs for men with BRCA and similar variants.
Outlook and survival rates
Most prostate cancers are found while still inside the gland. The ProtecT trial followed 1,643 men with PSA-detected localized prostate cancer for a median of 15 years: about 3 in 100 died of prostate cancer, with no significant difference between active monitoring, surgery and radiotherapy 6. Spread was more common with monitoring (9.4% versus about 5% with surgery or radiotherapy) 6, and the trade-offs differed: surgery caused the most urine leakage and erection problems, and radiotherapy more bowel effects. Most men in ProtecT had low-risk cancer, and monitoring has since become more intensive, with MRI.
Living with prostate cancer
After treatment, PSA becomes the main follow-up test. After surgery PSA should fall to almost undetectable; after radiotherapy it falls more slowly to a low point. A PSA that rises again, called biochemical recurrence, is often the first sign that prostate cancer is back, months or years before any symptom. After surgery that usually means a confirmed PSA of 0.2 ng/mL or higher 21; after radiotherapy, a rise of 2.0 ng/mL above the lowest value reached 22.
Erection problems after surgery or radiotherapy are common and often improve over one to two years, and pelvic floor exercises, medicines and devices help many men; the erectile dysfunction page covers the options. Men with high-risk or spread cancer are now offered inherited-gene (germline) testing, which can guide treatment and matters for their relatives.
Only a clinician can diagnose prostate cancer or rule it out. Go to the emergency department or call 911 if you cannot pass urine at all, if back pain comes with new leg weakness, numbness, or loss of bladder or bowel control, if fever and chills come with painful urination, or if there is heavy blood with clots in your urine. Book a doctor's appointment within days for any new change in urination, blood in the urine or semen, or bone pain you cannot explain. Do not start or stop finasteride, dutasteride, testosterone or any supplement to change a PSA result without your doctor: finasteride and dutasteride lower PSA by about half, which can hide a rising number. Saw palmetto and other prostate supplements do not treat or prevent prostate cancer and are no reason to put off a check.
Citations
- American Cancer Society. Signs and symptoms of prostate cancer. Last revised 2026
- National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NG12). Published 2015, last updated April 2026
- Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin 2025;75(1):10-45
- US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319(18):1901-1913
- Kasivisvanathan V et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION). N Engl J Med 2018;378(19):1767-1777
- Hamdy FC et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer (ProtecT). N Engl J Med 2023;388(17):1547-1558
- Wei JT et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol 2023;210(1):46-53
- American Cancer Society. Key statistics for prostate cancer
- American Cancer Society. Prostate cancer risk factors
- McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Am J Surg Pathol 1988;12(12):897-906
- National Institute of Diabetes and Digestive and Kidney Diseases. Benign prostatic hyperplasia (BPH)
- Gandaglia G et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 2014;74(2):210-216
- National Institute for Health and Care Excellence. Spinal metastases and metastatic spinal cord compression (NG234). 2023
- National Cancer Institute. Prostate-specific antigen (PSA) test fact sheet
- Oesterling JE et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270(7):860-864
- Catalona WJ et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279(19):1542-1547
- Etzioni RD et al. Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. J Urol 2005;174(3):877-881
- Bent S et al. Saw palmetto for benign prostatic hyperplasia (STEP). N Engl J Med 2006;354(6):557-566
- Barry MJ et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms (CAMUS). JAMA 2011;306(12):1344-1351
- Hugosson J et al. A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 2019;76(1):43-51
- Cookson MS et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report. J Urol 2007;177(2):540-545
- Roach M et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-974
- Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018;103(5):1715-1744
- NHS. PSA test
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.




